首页> 外文期刊>The Turkish journal of pediatrics. >Pulmonary complications following hematopoietic stem cell transplantation in children
【24h】

Pulmonary complications following hematopoietic stem cell transplantation in children

机译:儿童造血干细胞移植后的肺部并发症

获取原文
           

摘要

Pediatric data about early or long-term pulmonary complications of hematopoietic stem cell transplantation (HSCT) are limited. Here we aimed to evaluate children who were treated with HSCT in the last 10 years and developed pulmonary complications following HSCT and to determine their risk factors associated with pulmonary complications. In this retrospective study, we evaluated 195 patients for the development of pulmonary complications after HSCT within a 10 years of period. Pulmonary complications developed in 71 (36.4%) patients. Of the 71 patients who had pulmonary complications, 60 had one pulmonary complication, 11 had two pulmonary complications. Pulmonary complications were diagnosed as early in 42 (51.2%) and late in 40 (48.8%) episodes. Pulmonary complications were infectious in 28 (34.1%), noninfectious in 20 (24.4%) and both infectious and nonfectious in 34 (41.5%) episodes. Pulmonary complications developed significantly more frequently in patients with malignancy, congenital immune deficiency and with at least one pulmonary disease before HSCT. The number of patients who had myeloablative conditioning regimen was significantly higher in the group of patients without pulmonary complications than the group with pulmonary complications. However, in multivariate analysis, none of these variables were shown to be effective in predicting pulmonary complications after HSCT (p0.05). During follow up, 54 (65.8%) episodes recovered, 20 (24.3%) episodes resulted with death due to pulmonary complications, 6 (7.3%) episodes had chronic pulmonary disease (bronchiolitis obliterans (BO) and bronchiolitis obliterans organizing pneumonia (BOOP)); 2 patients (each patient with one episode) were lost to follow up. In conclusion; identifying children who are at risk for severe pulmonary complications and close longitudinal follow-up after HSCT by pediatric pulmonologists is mandatory to increase survival and life quality of these patients.
机译:有关造血干细胞移植(HSCT)早期或长期肺部并发症的儿科数据有限。在这里,我们旨在评估在过去10年中接受过HSCT治疗并在HSCT之后出现肺部并发症的儿童,并确定他们与肺部并发症相关的危险因素。在这项回顾性研究中,我们评估了195名患者在10年内HSCT后发生肺部并发症的情况。 71(36.4%)位患者发生了肺部并发症。在71例患有肺部并发症的患者中,60例患有肺部并发症,11例患有2例肺部并发症。肺部并发症被诊断为42例(51.2%)早期,40例(48.8%)晚期。肺部并发症的传染性为28(34.1%),非传染性为20(24.4%),传染性和非传染性均为34(41.5%)。恶性肿瘤,先天性免疫缺陷和HSCT前至少有一种肺部疾病的患者,肺部并发症的发生频率更高。在没有肺部并发症的患者组中,采用清髓疗法治疗方案的患者人数明显多于有肺部并发症的患者。但是,在多变量分析中,这些变量均未显示可有效预测HSCT后的肺部并发症(p> 0.05)。在随访期间,恢复了54(65.8%)次发作,由于肺部并发症导致死亡20次(24.3%),具有慢性肺部疾病(闭塞性细支气管炎(BO)和组织性肺炎的闭塞性细支气管炎(BOOP))发作了6次(7.3%) ); 2名患者(每名患者发作1次)失去随访。结论;小儿肺科医师必须识别出有严重肺部并发症风险并在HSCT后进行密切纵向随访的儿童,以提高这些患者的生存率和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号